Previous 10 | Next 10 |
Amneal Pharmaceuticals Inc. (AMRX) is expected to report $0.1 for Q3 2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. Chirag will present on January 10 ...
2023-12-15 16:09:17 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company Amneal Pharma in pact with Strides to launch generic Vascepa Amneal Pharmaceuticals Non-GAAP EPS of $0.19 beats by $0.06, revenue of $6...
- Nasdaq move will be effective on December 27, 2023 Amneal Pharmaceuticals, Inc. (“Amneal”) (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market (“Nasdaq”) from the New York Stock Exchange (“NYSEȁ...
2023-12-14 14:26:24 ET More on AbbVie, AstraZeneca, etc. GSK - Greenshoots In The Horizon AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 AbbVie, Amgen among firms targeted for latest Medi...
2023-12-09 22:23:45 ET Summary Amneal Pharmaceuticals' stock price has been on a strong bull run, now exceeding $5 per share, and up over >145% this year. The company experienced losses in 2018 and 2019 but has since seen improvements in revenues and net income, as the manageme...
ONGENTYS ® (opicapone) is a leading adjunctive therapy for the treatment of Parkinson’s Disease Complements Amneal’s existing Parkinson’s franchise and further expands specialty portfolio Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”...
2023-12-01 13:40:47 ET More on Amarin, Amneal, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Amarin Corporation plc (AMRN) Q3 2023 Earnings Call Transcript ...
- Partnering with Strides to commercialize recently U.S. FDA approved product - Represents another new product launch for Amneal in 2023 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) and Strides Pharma Science Limited (ȁ...
2023-11-07 15:19:08 ET Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Conference Call November 07, 2023 08:30 AM ET Company Participants Anthony DiMeo - Head-Investor Relations Chirag Patel - Co-Founder & Co-Chief Executive Officer Chintu Patel - Co-Fou...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...